Janssen Biotech, NYU Sued Over Neuro Treatment Patents

Law360, New York (August 16, 2012, 8:09 PM EDT) -- Tact IP LLC on Wednesday filed a suit against Janssen Biotech Inc. and New York University that sought to overturn a recent U.S. Patent and Trademark Office appeal board decision that rejected Tact's bid to claim priority for patents covering treatment for neurological conditions.

In a complaint filed in Virginia federal court, Tact sought to reverse an adverse judgment issued in June by the USPTO's Board of Patent Appeals and Interferences that ruled Tact was barred from claiming a majority of the inventions covered in two...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.